Stockscreener 앱 받기
3.26
0.31%
-0.01
시장 영업 전:
3.24
-0.02
-0.61%
전일 마감가:
$3.27
열려 있는:
$3.39
하루 거래량:
1.00M
Relative Volume:
2.59
시가총액:
$130.25M
수익:
$14.79M
순이익/손실:
$-102.44M
주가수익비율:
-1.0724
EPS:
-3.04
순현금흐름:
$-91.73M
1주 성능:
+5.50%
1개월 성능:
-21.63%
6개월 성능:
-60.34%
1년 성능:
-59.75%
1일 변동 폭
$3.08
$3.39
1주일 범위
$3.05
$3.39
52주 변동 폭
$3.03
$15.05
솔리드 바이오 Stock (SLDB) Company Profile
명칭
Solid Biosciences Inc
전화
617-337-4680
주소
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
SLDB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
3.26 | 130.25M | 14.79M | -102.44M | -91.73M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
솔리드 바이오 Stock (SLDB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-08 | 개시 | Truist | Buy |
| 2024-12-13 | 개시 | Wedbush | Outperform |
| 2024-12-10 | 개시 | JMP Securities | Mkt Outperform |
| 2024-07-15 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-06-24 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-05-31 | 재개 | Piper Sandler | Overweight |
| 2024-03-28 | 개시 | William Blair | Outperform |
| 2024-03-15 | 개시 | Citigroup | Buy |
| 2024-03-14 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-12-08 | 개시 | H.C. Wainwright | Buy |
| 2021-07-12 | 개시 | Piper Sandler | Neutral |
| 2021-05-27 | 개시 | Jefferies | Buy |
| 2021-03-16 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-09 | 개시 | Barclays | Overweight |
| 2021-01-08 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2020-07-28 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-05-07 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-10-11 | 개시 | Evercore ISI | Outperform |
| 2019-08-29 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2019-08-19 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-08-16 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2019-05-14 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2019-05-14 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-02-08 | 업그레이드 | Citigroup | Sell → Neutral |
| 2019-02-08 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2018-11-06 | 개시 | Citigroup | Sell |
| 2018-09-06 | 개시 | Credit Suisse | Neutral |
모두보기
솔리드 바이오 주식(SLDB)의 최신 뉴스
Solid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Rating of “Buy” from Analysts - Defense World
Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart - Seeking Alpha
Solid Biosciences gets FDA Fast Track for FA gene therapy - Investing.com India
Solid Biosciences' Ataxia Treatment Receives FDA Fast-Track Designation - MarketWatch
Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia - Yahoo Finance
Barclays PLC Acquires 50,582 Shares of Solid Biosciences Inc. (NASDAQ:SLDB) - Defense World
SLDB Stock Up as FDA Clears IND for SGT-212 in Friedreich's Ataxia - MSN
Solid Biosciences Initiates Clinical Trial For Duchenne Therapy SGT-003 - RTTNews
Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines - The Manila Times
Solid Biosciences Advances Gene Therapy Pipeline, Reports Strong $148.9M Cash Position - StockTitan
Solid Bio draws buy from Truist on valuation and catalysts - MSN
Jane Street Group LLC Has $145,000 Stock Holdings in Solid Biosciences Inc. (NASDAQ:SLDB) - Defense World
Solid Biosciences CFO Kevin Tan sells $15,849 in company stock By Investing.com - Investing.com Australia
Solid Biosciences CFO Kevin Tan sells $15,849 in company stock - Investing.com India
Kevin Tan Sells 4,073 Shares of Solid Biosciences Inc. (NASDAQ:SLDB) Stock - MarketBeat
Solid Biosciences' SWOT analysis: gene therapy firm's stock poised for growth - Investing.com
Q1 EPS Forecast for Solid Biosciences Reduced by Analyst - Defense World
HC Wainwright Reiterates “Buy” Rating for Solid Biosciences (NASDAQ:SLDB) - Defense World
Solid Biosciences stock hits 52-week low at $3.78 By Investing.com - Investing.com Australia
Solid Biosciences (NASDAQ:SLDB) Earns Buy Rating from HC Wainwright - MarketBeat
Solid Biosciences stock hits 52-week low at $3.78 - Investing.com
Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development (CORRECTED) - Benzinga
Solid Bio stock draws buy from Truist (SLDB:NASDAQ) - Seeking Alpha
Solid Biosciences (NASDAQ:SLDB) Earns Buy Rating from Analysts at Truist Financial - MarketBeat
Pre-market Movers: SANA, SLDB, JSPR, DRIO... - RTTNews
Truist Securities Initiates Coverage of Solid Biosciences (SLDB) with Buy Recommendation - MSN
FDA Nod Sends Solid Biosciences (SLDB) Soaring After-Hours - Stocks Telegraph
Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich’s Ataxia - Yahoo Finance
FDA clears Solid Biosciences' gene therapy IND for FA By Investing.com - Investing.com South Africa
Solid Biosciences director Ilan Ganot sells $4,551 in stock By Investing.com - Investing.com Canada
Solid Biosciences stock jumps 11% post-market on FDA update - MSN
FDA clears Solid Biosciences' gene therapy IND for FA - Investing.com India
Solid Biosciences director Ilan Ganot sells $4,551 in stock - Investing.com
Solid Biosciences Gains FDA Clearance for New Drug Application - MarketWatch
Solid Biosciences' Revolutionary Dual-Route Gene Therapy for Friedreich's Ataxia Gains FDA Clearance - StockTitan
Solid Biosciences Inc. (NASDAQ:SLDB) Shares Sold by Geode Capital Management LLC - Defense World
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Solid Biosciences Awards Stock Incentives to New Key Employee Under 2024 Plan - StockTitan
Solid Biosciences stock hits 52-week low at $3.9 amid challenges - Investing.com Australia
Solid Biosciences stock hits 52-week low at $3.9 amid challenges By Investing.com - Investing.com South Africa
State Street Corp Grows Stock Position in Solid Biosciences Inc. (NASDAQ:SLDB) - Defense World
Analysts Set Solid Biosciences Inc. (NASDAQ:SLDB) Price Target at $15.22 - MarketBeat
Solid Biosciences Inc. (NASDAQ:SLDB) Given Average Rating of “Buy” by Analysts - Defense World
SLDBSolid Biosciences Inc. Latest Stock News & Market Updates - StockTitan
Solid Biosciences Added to the Nasdaq Biotechnology Index - GlobeNewswire
솔리드 바이오 (SLDB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):